Jonathan I. Lieber - 30 Nov 2022 Form 4 Insider Report for APPLIED GENETIC TECHNOLOGIES CORP

Role: Chief Financial Officer
Signature: /s/ Stacie Aarestad, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 30 Nov 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Dec 2022, 08:15:20 UTC
Previous filing: 24 Aug 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGTC	Stock Option (Right to Buy)	Disposed to Issuer		-202,000	-100%		0	30 Nov 2022	Common Stock	202,000	$3.30	Direct	F1
transaction	AGTC	Stock Option (Right to Buy)	Disposed to Issuer		-154,700	-100%		0	30 Nov 2022	Common Stock	154,700	$0.4000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jonathan I. Lieber is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.

Remarks:

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 23, 2022, by and among Applied Genetic Technologies Corporation (the "Issuer"), Alliance Holdco Limited ("Parent") and Alliance Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on November 30, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").